ADPT
NASDAQ HealthcareAdaptive Biotechnologies Corporation - Common Stock
Biotechnology
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
๐ Market Data
| Price | $14.27 |
|---|---|
| Volume | 935,378 |
| Market Cap | 2.28B |
| Beta | 2.300 |
| RSI (14-Day) | 51.8 |
| 200-Day MA | $14.90 |
| 50-Day MA | $14.34 |
| 52-Week High | $20.76 |
| 52-Week Low | $8.38 |
| Forward P/E | -53.13 |
| Price / Book | 10.03 |
๐ฏ Investment Strategy Scores
ADPT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (95/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ADPT in your text
Paste any article, transcript, or post โ the tool will extract ADPT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.